Amphenol vs AstraZeneca: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Amphenol and AstraZeneca side by side

1. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

2. 1932Amphenol

   Arthur J. Schmitt founds American Phenolic Corporation

   Arthur J. Schmitt incorporates American Phenolic Corporation in Chicago with a patented molded phenolic radio tube socket, establishing the company's foundation in electronic component manufacturing.

3. 1936Amphenol

   Introduction of industry-standard 75 series microphone connector and lock-in socket

   Amphenol introduces the 75 series uniform microphone connector and a lock-in socket for radio tubes, both becoming industry standards and attracting RCA as a major customer ordering 10,000 sockets daily.

4. 1942Amphenol

   Primary supplier of AN connectors for WWII Allied forces

   Amphenol becomes a critical defense supplier, with its 5015 AN circular connectors becoming standard equipment on military aircraft and communications gear; A-N connector shipments increase 13,572% from January 1941 to March 1943.

5. 1942Amphenol

   Official name change to Amphenol Electronics Corporation

   The company officially changes its name from American Phenolic Corporation to Amphenol Electronics Corporation, formalizing the shorthand name customers had used for years.

6. 1945Amphenol

   Initial public offering

   Amphenol raises $1.5 million from convertible debentures and sells 345,000 shares at $10 per share, giving the company a $4 million market capitalization and providing capital for post-war diversification.

7. 1951Amphenol

   Amphenol engineers develop the BNC connector

   Amphenol engineers Paul Neill and Carl Concelman develop the bayonet coupled BNC coaxial connector, which becomes a standard interface in radio frequency and test equipment applications.

8. 1957Amphenol

   NYSE listing

   Amphenol Electronics Corporation lists on the New York Stock Exchange, marking its transition to a major public industrial company.

9. 1958Amphenol

   Merger with George W. Borg Corporation

   Amphenol completes its largest transaction to date, merging with the George W. Borg Corporation, a maker of automobile clocks, electronic instruments and deep pile fabrics, and is renamed Amphenol-Borg Electronics Corporation.

10. 1967Amphenol

    Acquisition by Bunker-Ramo Corporation

    Bunker-Ramo Corporation acquires Amphenol, which begins operating as a subsidiary and passes through successive corporate owners for the next 24 years.

11. 1981Amphenol

    Allied Corporation buys Bunker-Ramo for $358 million

    Allied Corporation acquires Bunker-Ramo for $358 million, including the Amphenol division, making Amphenol part of a larger industrial conglomerate.

12. 1987Amphenol

    LPL Investment leveraged buyout for $430 million

    LPL Investment buys Amphenol from Allied in a leveraged buyout valued at $430 million in cash, and the decentralized management style that defines the modern company takes hold. Martin H. Loeffler becomes president in the same year.

13. 1991Amphenol

    Second IPO on NYSE under ticker APH

    Amphenol returns to public markets with a second initial public offering on the New York Stock Exchange under ticker APH, beginning the modern era of sustained growth and shareholder returns.

14. 1993AstraZeneca

    Zeneca Group Spun Off from ICI

    Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

15. 1999AstraZeneca

    Astra and Zeneca Merge to Form AstraZeneca

    The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

16. 2000AstraZeneca

    Nexium Launch Replaces Prilosec

    AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

17. 2005Amphenol

    Acquisition of Teradyne connector business for $390 million

    Amphenol acquires Teradyne's connection systems business for $390 million in October 2005, expanding its presence in high speed data and backplane connectors for the growing IT datacom market.

18. 2006AstraZeneca

    Acquisition of Cambridge Antibody Technology

    AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

19. 2007AstraZeneca

    Acquisition of MedImmune for $15.6 Billion

    AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

20. 2012AstraZeneca

    Pascal Soriot Appointed CEO

    Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

21. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

22. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

23. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

24. 2016Amphenol

    Acquisition of FCI Asia for $1.275 billion

    Amphenol acquires FCI Asia from affiliates of Bain Capital for $1.275 billion in January 2016, strengthening its global connector footprint and adding high speed backplane and board-to-board capability.

25. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

26. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

27. 2021Amphenol

    Acquisition of MTS Systems Corporation for $1.7 billion

    Amphenol acquires MTS Systems for $1.7 billion in April 2021, adding advanced sensor capability that deepens its position in industrial and automotive sensing.

28. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

29. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

30. 2024Amphenol

    Acquisition of Carlisle Interconnect Technologies for about $2.0 billion

    Amphenol completes the purchase of Carlisle Interconnect Technologies from Carlisle Companies in May 2024 for about $2.0 billion, expanding aerospace, defense and medical harsh environment interconnect capability.

31. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

32. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

33. 2025Amphenol

    Completion of the $2.1 billion CommScope outdoor wireless and DAS purchase

    Amphenol completes the acquisition of CommScope's Outdoor Wireless Networks and Distributed Antenna Systems businesses, including Andrew, for $2.1 billion in cash. The businesses had about $1.2 billion of 2024 sales.

34. 2025Amphenol

    Record fiscal 2025 revenue of $23.09 billion, up 52%

    Amphenol reports record full year 2025 net sales of $23.09 billion, up 52% year over year and 38% organically, with a 25.4% GAAP operating margin, $4.4 billion of free cash flow and Communications Solutions sales up 91% to about $12.1 billion.

35. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

36. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

37. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

38. 2026Amphenol

    Completion of the $10.5 billion CommScope CCS acquisition

    Amphenol closes its largest acquisition, buying CommScope's Connectivity and Cable Solutions business for $10.5 billion on January 12, 2026. Amphenol also acquired the CommScope name and expects the business to generate about $4.1 billion of sales in 2026.

39. 2026Amphenol

    Norwitt named chairman as Loeffler retires from the board

    Amphenol announces on February 4, 2026 that chief executive R. Adam Norwitt will also become chairman of the board at the May 2026 annual meeting, as Martin H. Loeffler retires from the board after more than five decades with the company.

40. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

41. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

42. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

Acquisitions

Questions about Amphenol vs AstraZeneca